Disease modifying therapies for alzheimer's disease targeting a β oligomers: Implications for therapeutic mechanisms

9Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Several lines of evidence indicate that amyloid β (Aβ), particularly Aβ oligomers (AβOs), plays a causative role in Alzheimer's disease. However, the mechanisms underlying the action of an anti-AβO antibody to clarify the toxic action of AβOs remain elusive. Here, we showed that the anti-AβO antibody (monoclonal 72D9) can modify the Aβ aggregation pathway. We also found that 72D9 directly sequesters both extracellular and intraneuronal AβOs in a nontoxic state. Thus, therapeutic intervention targeting AβOs is a promising strategy for neuronal protection in Alzheimer's disease. © 2013 Etsuro Matsubara et al.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Matsubara, E., Takamura, A., Okamoto, Y., Oono, H., Nakata, T., Wakasaya, Y., … Shoji, M. (2013). Disease modifying therapies for alzheimer’s disease targeting a β oligomers: Implications for therapeutic mechanisms. BioMed Research International, 2013. https://doi.org/10.1155/2013/984041

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

42%

Researcher 5

42%

Professor / Associate Prof. 2

17%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 6

46%

Medicine and Dentistry 3

23%

Biochemistry, Genetics and Molecular Bi... 3

23%

Chemistry 1

8%

Save time finding and organizing research with Mendeley

Sign up for free